Actively Recruiting
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
Led by Bristol-Myers Squibb · Updated on 2024-04-25
600
Participants Needed
2
Research Sites
310 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, observational, real-world study of adult participants in Japan with physician-reported diagnosis of plaque psoriasis treated with deucravacitinib or apremilast.
CONDITIONS
Official Title
A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Japanese adults aged 18 years or older
- Physician-confirmed diagnosis of plaque psoriasis
- Newly starting treatment with deucravacitinib or apremilast as per product label
- Signed informed consent to participate in the study
You will not qualify if you...
- Currently participating or planning to participate in an interventional clinical trial
- Enrolled in the deucravacitinib post-marketing surveillance study (NCT05633264)
- Previous treatment with deucravacitinib or apremilast (not eligible for the treated arm)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mebix. Inc.
Minato-ku, Tokyo, Japan, 1070052
Actively Recruiting
2
Fukuoka University Hospital
Fukuoka, Japan
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here